This supplement provides an overview of the development of perampanel, the first non-competitive AMPA-type glutamate receptor antagonist to be developed as an adjunctive treatment for refractory partial-onset seizures. Introduction.

This supplement provides an overview of the development of perampanel, the first non-competitive AMPA-type glutamate receptor antagonist to be developed as an adjunctive treatment for refractory partial-onset seizures. Introduction. Acta Neurol Scand Suppl. 2013;(197):1-2 Authors: Ben-Menachem E PMID: 23480149 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/23480149?dopt=Abstract

Source: Acta Neurologica Scandinavica. Supplementum - May 25, 2013 Category: Neurology Authors: Ben-Menachem E Tags: Acta Neurol Scand Suppl Source Type: research

More News: Men | Neurology | PET Scan